共 116 条
[1]
Campbell CM(2020)Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis? Circulation. 141 1739-1741
[2]
Kahwash R(2012)Epidemiology and clinical manifestations of mucormycosis Clin Infect Dis 54 S23-S34
[3]
Petrikkos G(2015)Changing epidemiology of mucoralean fungi: chronic cutaneous infection caused by mucor irregularis Mycopathologia 180 181-186
[4]
Skiada A(2020)Epidemiological and clinical characteristics of 99 cases of 2019 621 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet (London, England) 395 507-13
[5]
Lortholary O(2021)Rising incidence of mucormycosis in patients with COVID-19: another challenge for India admits the second wave Lancet Respiratory Med 13 236-301
[6]
Roilides E(2002)In human disease Clin Microbiol Rev 18 556-569
[7]
Walsh TJ(2005)Novel perspectives on mucormycosis: pathophysiology, presentation, and management Clin Microbiol Rev 24 168-171
[8]
Kontoyiannis DP(2020)Mucormycosis in a tertiary care center in South India: a 4-year experience Indian J Crit Care Med Peer-Reviewed Off Publ Indian Soc Crit Care Med 15 e533-e540
[9]
Chander J(2011)Mucormycosis in immunocompetent patients: A case-series of patients with maxillary sinus involvement and a critical review of the literature Int J Infect Dis IJID Off Publ Int Soc Infect Dis 14 1563-1569
[10]
Kaur M(2020)Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature Diabetes Metab Syndr 186 289-298